Agios Pharmaceuticals Inc
AGIO · NASDAQ
Agios is focused on discovering and developing novel investigational medicines to treat malignant hematology, solid tumors and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across these three therapeutic areas, Agios has two approved oncology precision medicines and multiple first-in-class investigational therapies in clinical and/or preclinical development.
ESG Scores
Overall ESG3.6
Environmental3.2
Social3.2
Governance6.1
Gender Diversity
Female Directors0.4%
Female Executives0.3002070393374741%
Women in Workforce0.569%
CEO GenderMale
Market Data
Price$27.07-8.07 (-22.97%)
Market Cap$1.54B
P/E Ratio—
EPS$—
52W High$46.00
52W Low$22.24
Beta0.77